Marc Weiner1, Radojka M Savic2, William R Mac Kenzie3, Diane Wing4, Charles A Peloquin5, Melissa Engle4, Erin Bliven3, Thomas J Prihoda6, Jonathan A L Gelfond7, Nigel A Scott3, Susan M Abdel-Rahman8, Gregory L Kearns8, William J Burman9, Timothy R Sterling10, M Elsa Villarino3. 1. Department of Medicine, University of Texas Health Science Center, San Antonio Veterans Administration Medical Center, San Antonio, Texas. 2. University of California at San Francisco, School of Pharmacy, Bioengineering and Therapeutic Sciences. 3. Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia. 4. Department of Medicine, University of Texas Health Science Center, San Antonio. 5. University of Florida, College of Pharmacy, Gainesville. 6. Department of Pathology, University of Texas Health Science Center, San Antonio. 7. Department of Epidemiology and Biostatistics, University of Texas Health Science Center, San Antonio. 8. Pediatrics, Children's Mercy Hospitals and Clinics, Kansas City, Missouri. 9. Denver Health, Denver Public Health, Colorado. 10. Vanderbilt Universities, Medicine, Nashville, Tennessee.
Abstract
BACKGROUND: In a phase 3, randomized clinical trial (PREVENT TB) of 8053 people with latent tuberculosis infection, 12 once-weekly doses ofrifapentine and isoniazid had good efficacy and tolerability. Children received higher rifapentine milligram per kilogram doses than adults. In the present pharmacokinetic study (a component of the PREVENT TB trial), rifapentine exposure was compared between children and adults. METHODS:Rifapentine doses in children ranged from 300 to 900 mg, and adults received 900 mg. Children who could not swallow tablets received crushed tablets. Sparse pharmacokinetic sampling was performed with 1 rifapentine concentration at 24 hours after drug administration (C24). Rifapentine area under concentration-time curve (AUC) was estimated from a nonlinear, mixed effects regression model (NLME). RESULTS: There were 80 children (age: median, 4.5 years; range, 2-11 years) and 77 adults (age: median, 40 years; all ≥18 years) in the study. The geometric mean rifapentine milligram per kilogram dose was greater in children than in adults (children, 23 mg/kg; adults, 11 mg/kg). Rifapentine geometric mean AUC and C24 were 1.3-fold greater in children (all children combined) than in adults. Children who swallowed whole tablets had 1.3-fold higher geometric mean AUC than children who received crushed tablets, and children who swallowed whole tablets had a 1.6-fold higher geometric mean AUC than adults. The higher rifapentine doses in children were well tolerated. To obtain rifapentine exposures comparable in children to adults, dosing algorithms modeled by NLME were developed. CONCLUSIONS: A 2-fold greater rifapentine dose for all children resulted in a 1.3-fold higher AUC compared to adults administered a standard dose. Use of higher weight-adjusted rifapentine doses for young children are warranted to achieve systemic exposures that are associated with successful treatment of latent tuberculosis infection in adults. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society 2014. This work is written by US Government employees and is in the public domain in the US.
RCT Entities:
BACKGROUND: In a phase 3, randomized clinical trial (PREVENT TB) of 8053 people with latent tuberculosis infection, 12 once-weekly doses of rifapentine and isoniazid had good efficacy and tolerability. Children received higher rifapentine milligram per kilogram doses than adults. In the present pharmacokinetic study (a component of the PREVENT TB trial), rifapentine exposure was compared between children and adults. METHODS:Rifapentine doses in children ranged from 300 to 900 mg, and adults received 900 mg. Children who could not swallow tablets received crushed tablets. Sparse pharmacokinetic sampling was performed with 1 rifapentine concentration at 24 hours after drug administration (C24). Rifapentine area under concentration-time curve (AUC) was estimated from a nonlinear, mixed effects regression model (NLME). RESULTS: There were 80 children (age: median, 4.5 years; range, 2-11 years) and 77 adults (age: median, 40 years; all ≥18 years) in the study. The geometric mean rifapentine milligram per kilogram dose was greater in children than in adults (children, 23 mg/kg; adults, 11 mg/kg). Rifapentine geometric mean AUC and C24 were 1.3-fold greater in children (all children combined) than in adults. Children who swallowed whole tablets had 1.3-fold higher geometric mean AUC than children who received crushed tablets, and children who swallowed whole tablets had a 1.6-fold higher geometric mean AUC than adults. The higher rifapentine doses in children were well tolerated. To obtain rifapentine exposures comparable in children to adults, dosing algorithms modeled by NLME were developed. CONCLUSIONS: A 2-fold greater rifapentine dose for all children resulted in a 1.3-fold higher AUC compared to adults administered a standard dose. Use of higher weight-adjusted rifapentine doses for young children are warranted to achieve systemic exposures that are associated with successful treatment of latent tuberculosis infection in adults. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society 2014. This work is written by US Government employees and is in the public domain in the US.
Authors: Michelle M Pham; Anthony T Podany; Noluthando Mwelase; Khuanchai Supparatpinyo; Lerato Mohapi; Amita Gupta; Wadzanai Samaneka; Ayotunde Omoz-Oarhe; Deborah Langat; Constance A Benson; Richard E Chaisson; Susan Swindells; Courtney V Fletcher Journal: Antimicrob Agents Chemother Date: 2022-08-09 Impact factor: 5.938
Authors: Marc Weiner; Eric F Egelund; Melissa Engle; Melissa Kiser; Thomas J Prihoda; Jonathan A L Gelfond; William Mac Kenzie; Charles A Peloquin Journal: J Antimicrob Chemother Date: 2013-12-15 Impact factor: 5.790
Authors: R Court; M T Chirehwa; L Wiesner; N de Vries; J Harding; T Gumbo; G Maartens; H McIlleron Journal: Int J Tuberc Lung Dis Date: 2019-10-01 Impact factor: 2.373
Authors: Taylor W Foreman; Allison N Bucşan; Smriti Mehra; Charles Peloquin; Lara A Doyle; Kasi Russell-Lodrigue; Neel R Gandhi; John Altman; Cheryl L Day; Joel D Ernst; Henry M Blumberg; Jyothi Rengarajan; Deepak Kaushal Journal: Am J Respir Crit Care Med Date: 2020-02-15 Impact factor: 30.528
Authors: I H Bartelink; N Zhang; R J Keizer; N Strydom; P J Converse; K E Dooley; E L Nuermberger; R M Savic Journal: Clin Transl Sci Date: 2017-05-31 Impact factor: 4.689